Advertisement

Drugs

, Volume 67, Issue 8, pp 1109–1124 | Cite as

Hormone-Refractory Prostate Cancer

Where are We Going?
  • Giuseppe Di Lorenzo
  • Riccardo Autorino
  • William D. Figg
  • Sabino De Placido
Leading Article

Abstract

This article addresses the current status of therapeutic options in the management of hormone-refractory prostate cancer (HRPC). Following the publication of two landmark randomised trials, docetaxel chemotherapy is now the standard of care for men with metastatic HRPC. However, the benefit of this treatment is limited. Trials are now focusing on improving the efficacy of docetaxel by combining it with novel biological agents. Several new docetaxel-based combinations are under evaluation and promising results have been found for the combination of docetaxel with angiogenesis inhibitors. Early phase III trial data for atrasentan appear interesting. New cytotoxic agents such as satraplatin and ixabepilone are being investigated in several ongoing studies in order to define their role as second-line treatments of HRPC. Vaccine therapy offers an active immunological approach for combating malignancy in a targeted manner.

Keywords

Prostate Cancer Docetaxel Androgen Receptor Zoledronic Acid Vinorelbine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

No sources of funding were used to assist in the preparation of this article. The authors have no conflicts of interest that are directly relevant to the content of this article.

References

  1. 1.
    Jamal A, Murray T, Ward E, et al. Cancer statistics 2006. CA Cancer J Clin 2006; 56: 106–30CrossRefGoogle Scholar
  2. 2.
    Scher HI, Steineck G, Kelly WK. Hormone-refractory (D3) prostate cancer: refining the concept. Urology 1995; 46: 142–8PubMedCrossRefGoogle Scholar
  3. 3.
    Yagoda A, Petrylak DP. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 1993; 71: 1098–109PubMedCrossRefGoogle Scholar
  4. 4.
    Tannock IF, Osaba D, Stockier MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone resistant prostate cancer: a Canadian randomised trial with palliative end-point. J Clin Oncol 1996; 14: 1764–5Google Scholar
  5. 5.
    Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol 1999; 17: 2506–13PubMedGoogle Scholar
  6. 6.
    Tannock IF, de Wit R, Berry W, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502–12PubMedCrossRefGoogle Scholar
  7. 7.
    Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513–20PubMedCrossRefGoogle Scholar
  8. 8.
    Clarke NW, Wylie JP. Chemotherapy in hormone refractory prostate cancer: where do we stand? Eur Urol 2004; 46:709–11PubMedCrossRefGoogle Scholar
  9. 9.
    Di Lorenzo G, Autorino R, Perdona S, et al. Docetaxel, vinorelbine and zoledronic acid in patients with hormone refractory prostate cancer. Eur Urol. In pressGoogle Scholar
  10. 10.
    Goodin S, Rao KV, Kane M, et al. A phase II trial of docetaxel and vinorelbine in patients with hormone-refractory prostate cancer. Cancer Chemother Pharmacol 2005; 56: 199–204PubMedCrossRefGoogle Scholar
  11. 11.
    Oh WK, Halabi S, Kelly WK, et al. A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813. Cancer 2003; 98 (12): 2592–8PubMedCrossRefGoogle Scholar
  12. 12.
    Ferrero JM, Chamorey E, Oudard S, et al. Phase II trial evaluating a docetaxel-capecitabine combination as treatment for hormone-refractory prostate cancer. Cancer 2006; 107 (4): 738–45PubMedCrossRefGoogle Scholar
  13. 13.
    Ryan CW, Stadler WM, Vogelzang NJ, et al. A phase I/II dose escalation study of exisulind and docetaxel in patients with hormone refractory prostate cancer. BJU Int 2005; 95 (7): 963–8PubMedCrossRefGoogle Scholar
  14. 14.
    Font A, Murias A, Arroyo FR, et al. Sequential mitoxantrone/ prednisone followed by docetaxel/estramustine in patients with hormone refractory metastatic prostate cancer: results of a phase II study. Ann Oncol 2005; 16: 419–24PubMedCrossRefGoogle Scholar
  15. 15.
    Beer TM, Eilers KM, Garzotto M, et al. Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol 2003; 21: 123–8PubMedCrossRefGoogle Scholar
  16. 16.
    Kreis W, Budman DR, Calabro A. Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines. Br J Urol 1997; 79: 196–202PubMedCrossRefGoogle Scholar
  17. 17.
    Miller VA, Krug LM, Ng KK, et al. Phase II trial of docetaxel and vinorelbine in patients with advanced non small cell lung cancer. J Clin Oncol 2000; 18: 1346–50PubMedGoogle Scholar
  18. 18.
    Abratt RD, Brune D, Dimopoulos MA, et al. Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone refractory prostate cancer. Ann Oncol 2004; 15 (11): 1613–21PubMedCrossRefGoogle Scholar
  19. 19.
    Beer TM, Ryan CW, Venner PM, et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol 2007; 25 (6): 669–74PubMedCrossRefGoogle Scholar
  20. 20.
    Latif T, Wood L, Connel C, et al. Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) given daily x 5 in hormone refractory prostate cancer (HRPC). Invest New Drugs 2005; 23: 79–84PubMedCrossRefGoogle Scholar
  21. 21.
    Sternberg CN, Whelan P, Hetherington J, et al. Genitourinary Tract Group of the EORTC, 2005. Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology 2005; 68: 2–9Google Scholar
  22. 22.
    Calafro F, Sternberg CN. Current indications for chemotherapy in prostate cancer patients. Eur Urol 2007; 51 (1): 17–26CrossRefGoogle Scholar
  23. 23.
    Senzer N, Arsenau J, Richard D, et al. Irofulven demonstrates clinical activity against metastatic hormone refractory prostate cancer in a phase single agent trial. Am J Clin Oncol 2005; 28 (1): 36–42PubMedCrossRefGoogle Scholar
  24. 24.
    Fiedler W, Tchen N, Bloch J, et al. A study from the EORTC New Drug Development Group: open label phase II study of sabarubicin in patients with progressive hormone refractory prostate cancer. Eur J Cancer 2006; 42 (2): 200–4PubMedCrossRefGoogle Scholar
  25. 25.
    Daliani DD, Assikis V, Tu SM, et al. Phase II trial of cyclophosphamide, vincristine and dexamethasone in the treatment of androgen-independent prostate carcinoma. Cancer 2003; 97: 561–7PubMedCrossRefGoogle Scholar
  26. 26.
    Glode LM, Barqwi A, Crighton F, et al. Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma. Cancer 2003; 98: 1643–8PubMedCrossRefGoogle Scholar
  27. 27.
    Di Lorenzo G, Autorino R, Morelli E, et al. Thalidomide in combination with oral daily cyclophosphamide in patients with hormone refractory prostate cancer: a phase I clinical study. Cancer Biol Ther 2007; 6 (3): 5–11Google Scholar
  28. 28.
    Michels J, Montemurro T, Murray N, et al. First and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone refractory prostate cancer. Cancer 2006; 106: 1041–6PubMedCrossRefGoogle Scholar
  29. 29.
    Saad F, Ruether D, Ernst S, et al. Canadian Urologic Oncology Group (CUOG) phase II multicenter study using docetaxel/ prednisone in the second line setting for metastatic hormone refractory prostate cancer in patients progressing after first line mitoxantrone/prednisone [abstract]. Proc Am Soc Clin Oncol 2005; 23 (16S): 4612Google Scholar
  30. 30.
    Oh WK, Manola J, Babcic V, et al. Response to second line chemotherapy in patients with HRPC receiving two sequences of mitoxantrone and taxanes. Urology 2006; 67 (6): 1235–40PubMedCrossRefGoogle Scholar
  31. 31.
    Abbruzzese J. Phase I studies with the novel nucleoside analog, gemcitabine. Semin Oncol 1996; 23: 25–31PubMedGoogle Scholar
  32. 32.
    Morant R, Bernhard J, Maibach R, et al. Response and palliation in a phase II trial of gemcitabine in hormone refractory metastatic prostate cancer. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 2000; 11 (2): 183–8Google Scholar
  33. 33.
    Di Lorenzo G, Autorino R, Giuliano M, et al. Phase II trial of gemcitabine, prednisone and zoledronic acid in pre-treated patients with hormone refractory prostate cancer. Urology 2007; 69 (2): 347–51PubMedCrossRefGoogle Scholar
  34. 34.
    Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001; 1: 34–45PubMedCrossRefGoogle Scholar
  35. 35.
    Ropke A, Erbersdobler A, Hammerer P, et al. Gain of androgen receptor gene copies in primary prostate cancer due to X chromosome polysomy. Prostate 2004; 59 (1): 59–68PubMedCrossRefGoogle Scholar
  36. 36.
    Gregory CW, Johnson RT Jr, Mohler JL, et al. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 2001; 61 (7): 2892–8PubMedGoogle Scholar
  37. 37.
    Bakin RE, Gioeli D, Sikes RA, et al. Constitutive activation of the RAS/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res 2003; 63 (8): 1981–9PubMedGoogle Scholar
  38. 38.
    Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 2003; 349 (4): 366–81PubMedCrossRefGoogle Scholar
  39. 39.
    Culig Z, Hobisch A, Cronauer MV, et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-1, keratinocyte growth factor and epidermal growth factor. Cancer Res 1994; 54 (20): 5474–8PubMedGoogle Scholar
  40. 40.
    Lin HK, Yen S, Kang HY, et al. Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor. Proc Natl Acad Sci U S A 2001; 98 (13): 7200–5PubMedCrossRefGoogle Scholar
  41. 41.
    Wilding G, Soulie P, Trump D, et al. Results from a pilot phase I of gefitinib combined with docetaxel and estramustine in patients with hormone refractory prostate cancer. Cancer 2006; 106 (9): 1917–24PubMedCrossRefGoogle Scholar
  42. 42.
    Kim SJ, Uehara H, Yazici S, et al. Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer. J Natl Cancer Inst 2006; 98 (11): 783–93PubMedCrossRefGoogle Scholar
  43. 43.
    Mathew P, Thall PF, Johnson MM, et al. Preliminary results of a randomized placebo-controlled double-blind trial of weekly docetaxel combined with imatinib in men with metastatic androgen-independent prostate cancer (AIPC) and bone metastases (BM) [abstract]. ASCO Annual Meeting Proceedings 2006; 24 (18S) (June 20 Suppl.): y4562Google Scholar
  44. 44.
    Chee KG, Longmate J, Lara PN Jr, et al. Trastuzumab plus docetaxel in Her /2. Cancer 2004; 100: 2125–30PubMedCrossRefGoogle Scholar
  45. 45.
    de Bono JS, Bellmunt J, Attard G, et al. Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer. J Clin Oncol 2007; 25: 257–62PubMedCrossRefGoogle Scholar
  46. 46.
    Lara PN Jr, Twardowski P, Quinn DJ. Angiogenesis targeted therapies in prostate cancer. Clin Prostate Cancer 2004; 3 (3): 165–73PubMedCrossRefGoogle Scholar
  47. 47.
    Dahut WL, Gulley JL, Arlen PM, et al. Randomized phase II trial of docetaxel plus thalidomide in androgen independent prostate cancer. J Clin Oncol 2004; 22: 2532–7PubMedCrossRefGoogle Scholar
  48. 48.
    Cox MC, Dahut WL, Figg WD. The use of thalidomide in androgen independent prostate cancer. Urologic Oncol 2006; 24: 246–9CrossRefGoogle Scholar
  49. 49.
    Picus J, Halabi S, Rini B, et al. The use of bevacizumab with docetaxel and estramustine in hormone refractory prostate cancer: initial results of CALGB 900006 [abstract]. Proc Am Soc Clin Oncol 2003; 22: 393Google Scholar
  50. 50.
    Berry W, Eisenberger M. Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy. Oncologist 2005; 10 Suppl. 3: 30–9PubMedCrossRefGoogle Scholar
  51. 51.
    Carducci M, Padley RJ, Breul J, et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 2003; 4: 679–89CrossRefGoogle Scholar
  52. 52.
    Vogelzang NJ, Nelson JB, Schulman CC, et al. Meta-analysis of clinical trials of atrasentan 10mg in metastatic hormone-refractory prostate cancer [abstract no. 4615]. Proc Am Soc Clin Oncol 2005; 23: 406sGoogle Scholar
  53. 53.
    George DJ, Cockerman JP, Petrow W, et al. A phase I/II study of docetaxel and atrasentan in men with metastatic hormone-refractory prostate cancer (HRPC) [abstract]. J Clin Oncol, 2005 ASCO Annual Meeting Proceedings; 23 Suppl. 16S: 4667Google Scholar
  54. 54.
    Tolcher AW, Chi K, Kuhn J, et al. A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res 2005; 11: 3854–61PubMedCrossRefGoogle Scholar
  55. 55.
    Sternberg CN. Soup to nuts [online]. Prostate cancer symposium 2007 Feb 22–24; Orlando (FL). Available from URL: http://www.prostateline.org [Accessed 2007 May 9]
  56. 56.
    Hussain M, Tangen CM, Lara PN Jr, et al. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial SO 111. J Clin Oncol 2005; 23 (34): 8724–9PubMedCrossRefGoogle Scholar
  57. 57.
    Galsky MD, Small EJ, Oh WK, et al. Multi-institutional randomized phase II trial of the epothilone B analogue ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol 2005; 23: 1439–46PubMedCrossRefGoogle Scholar
  58. 58.
    Rosenberg JE, Weinberg VK, Kelly WK, et al. Randomized phase II study of ixabepilone or mitoxantrone and prednisone in patients with taxane resistant hormone refractory prostate cancer [abstract]. Proceedings from the 2006 Prostate Cancer Symposium, 2005 Feb 17–19, Orlando (FL): 253Google Scholar
  59. 59.
    Miyake H, Nelson C, Rennie PS, et al. Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. Cancer Res 2000; 60: 170–6PubMedGoogle Scholar
  60. 60.
    Chi KN, Eisenhauer E, Fazli L, et al. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst 2005; 97: 1287–96PubMedCrossRefGoogle Scholar
  61. 61.
    Chi KN, Eisenhauer E, Siu L, et al. A phase I study of a second generation antisense oligonucleotide to clusterin (OGX-011) in combination with docetaxel: NCIC CTG IND.154 [abstract]. J Clin Oncol, 2005 ASCO Annual Meeting Proceedings; 23 Suppl. 16S: 3085Google Scholar
  62. 62.
    Rowinsky EK, Calvo E. Novel agents that target tubulin and related elements. Semin Oncol 2006; 33 (4): 421–35PubMedCrossRefGoogle Scholar
  63. 63.
    Jordan MA, Kamath K, Manna T, et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 2005 Jul; 4 (7): 1086–95PubMedCrossRefGoogle Scholar
  64. 64.
    Beekman KW, Colevas AD, Cooney K, et al. Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design. Clin Genitourin Cancer 2006; 4 (4): 299–302PubMedCrossRefGoogle Scholar
  65. 65.
    Fu Y, Hsieh TC, Guo J, et al. Licochalcone-A, a novel flavonoid isolated from licorice root (Glycyrrhiza glabra), causes G2 and late-G1 arrests in androgen-independent PC-3 prostate cancer cells. Biochem Biophys Res Commun 2004; 322 (1): 263–70PubMedCrossRefGoogle Scholar
  66. 66.
    Small EJ, Schellammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006; 24 (19): 3089–94PubMedCrossRefGoogle Scholar
  67. 67.
    Brand TC, Tolcher AW. Management of high risk metstatic prostate cancer: the case of novel therapies. J Urol 2006; 176: S76–80PubMedCrossRefGoogle Scholar
  68. 68.
    Simons J, Higano C, Corman J. A phase I/II trial of high dose allogeneic GM-CSF gene-transduced prostate cancer cell line vaccine in patients with metastatic hormone-refractory prostate cancer [abstract]. Proc Am Soc Clin Oncol 2003; 22: 166CrossRefGoogle Scholar
  69. 69.
    Dipaola R, Plante M, Kaufman H, et al. A phase I trial of pox PSA vaccines (PROSTVACR-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM™) in patients with prostate cancer. J Transi Med 2006; 3: 1–5CrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2007

Authors and Affiliations

  • Giuseppe Di Lorenzo
    • 1
  • Riccardo Autorino
    • 2
  • William D. Figg
    • 3
  • Sabino De Placido
    • 1
  1. 1.Department of Clinical and Molecular OncologyFederico II UniversityNaplesItaly
  2. 2.Urologic ClinicSecond UniversityNaplesItaly
  3. 3.Molecular Pharmacology Section, Medical Oncology Branch, Center for Cancer ResearchNational Cancer InstituteBethesdaUSA

Personalised recommendations